Phaseline

Companies › NeuroDerm

NeuroDerm: clinical trials, targets and expected readouts

2 active drug programs in 11 registered trials: 4 Phase 3, 4 Phase 2, 2 Phase 4, 1 Phase 1; Neurology, Other, Psychiatry; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IR-LD/CD–Phase 3Parkinson's DiseaseFeb 2027
Levodopa (ND0612)
Dopamine D3 receptor agonist
DRD3Phase 3Parkinson's Disease; Freezing of Gait; Parkinson Disease; Acute Stroke …Feb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04558112Levodopa (ND0612)Phase 2PTSDPsychiatryDec 2023
NCT05463367Levodopa (ND0612)Phase 2Opioid UsePsychiatryJun 2025
NCT06831500Levodopa (ND0612)Phase 1Multi-system Atrophy - Parkinsonian TypeNeurologyNov 2026
NCT06316232Levodopa (ND0612)Phase 4Freezing of GaitNeurologyDec 2026
NCT04006210IR-LD/CDPhase 3Parkinson's DiseaseNeurologyFeb 2027
NCT04006210Levodopa (ND0612)Phase 3Parkinson's DiseaseNeurologyFeb 2027
NCT02726386Levodopa (ND0612)Phase 2Parkinson's DiseaseNeurologyFeb 2027
NCT06234995Levodopa (ND0612)Phase 4Parkinson DiseaseNeurologySep 2027
NCT05285683Levodopa (ND0612)Phase 2Chronic PainOtherDec 2027
NCT03735901Levodopa (ND0612)Phase 3Acute StrokeNeurologyJun 2029
NCT07151378Levodopa (ND0612)Phase 3PARKINSON DISEASE (Disorder)NeurologySep 2030

From the company's SEC filings

Complete response letters from FDA

Targets

DRD3 (1)

Companies with the same targets

LB Pharmaceuticals Gedeon Richter Serina Therapeutics Boryung Pharmaceutical Anxo Pharmaceutical Mapi Pharma AbbVie Navamedic MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals

Companies built like this

Navamedic MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals Sichuan Jishengtang Pharmaceutical Pharmasoft Epygenix

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.